CCA
EIDX

Catalyst Capital Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Catalyst Capital Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$6K – 564
2018
Q2 		$6K Buy
+300
New +$6.29K ﹤0.01% 431

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Catalyst Capital Advisors's EIDX Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2018, closing a stake of 300 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in EIDX in Q2 2018 and held it in 1 quarter. The position peaked at $6K in Q2 2018. 58 funds tracked by Wall St. Rank hold EIDX as of Q3 2018.

  • Catalyst Capital Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 300 Eidos Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $6K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.